Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving bad and noxa activation in human myeloid tumor cells

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Merhi, Faten ^a   Tang, Ruoping ^a,b   Piedfer, Marion ^a   Mathieu, Julie ^c   Bombarda, Isabelle ^d   Zaher, Murhaf ^a   Kolb, Jean Pierre ^a   Billard, Christian ^a   Bauvois, Brigitte ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; HYPERFORIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLSERINE; PROTEIN AKT1; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN NOXA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHLOROGLUCINOL; PMAIP1 PROTEIN, HUMAN; TERPENE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPHOSPHORYLATION; DNA FRAGMENTATION; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EX VIVO STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LEUKEMIA CELL; PRIMARY TUMOR; UPREGULATION; ADULT; AGED; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; FEMALE; INTRACELLULAR SPACE; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; INTRACELLULAR SPACE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANES; NF-KAPPA B; PHLOROGLUCINOL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TERPENES; UP-REGULATION;

EID: 80053617865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025963     Document Type: Article

References (80)

1. Calixto JB, Campos MM, Otuki MF, Santos AR, (2004) Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 70: 93-103.
2. Calixto JB, Otuki MF, Santos AR, (2003) Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB). Planta Med 69: 973-983.
3. Bailly C, (2009) Ready for a comeback of natural products in oncology. Biochem Pharmacol 77: 1447-1457.
4. Medina MA, Martinez-Poveda B, Amores-Sanchez MI, Quesada AR, (2006) Hyperforin: more than an antidepressant bioactive compound? Life Sci 79: 105-111.
5. Quiney C, Billard C, Salanoubat C, Fourneron JD, Kolb JP, (2006) Hyperforin, a new lead compound against the progression of cancer and leukemia? Leukemia 20: 1519-1525.
6. Borrelli F, Izzo AA, (2009) Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. Aaps J 11: 710-727.
7. Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC, (2010) Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. Curr Med Chem 17: 391-406.
8. Feisst C, Pergola C, Rakonjac M, Rossi A, Koeberle A, et al. (2009) Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 66: 2759-2771.
9. Dell'Aica I, Caniato R, Biggin S, Garbisa S, (2007) Matrix proteases, green tea, and St. John's wort: biomedical research catches up with folk medicine. Clin Chim Acta 381: 69-77.
10. Lorusso G, Vannini N, Sogno I, Generoso L, Garbisa S, et al. (2009) Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer 45: 1474-1484.
11. Rothley M, Schmid A, Thiele W, Schacht V, Plaumann D, et al. (2009) Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125: 34-42.
12. Hostanska K, Reichling J, Bommer S, Weber M, Saller R, (2003) Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 56: 121-132.
13. Liu JY, Liu Z, Wang DM, Li MM, Wang SX, et al. (2011) Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway. Chem Biol Interact 190: 91-101.
14. Quiney C, Billard C, Faussat AM, Salanoubat C, Ensaf A, et al. (2006) Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 20: 491-497.
15. Zaher M, Akrout I, Mirshahi M, Kolb JP, Billard C, (2009) Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol. Leukemia 23: 594-596.
16. King ME, Rowe JM, (2007) Recent developments in acute myelogenous leukemia therapy. Oncologist 12 (Suppl 2): 14-21.
17. Mason KD, Juneja SK, Szer J, (2006) The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 20: 71-82.
18. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, et al. (2008) Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer 112: 572-580.
19. Newcomb EW, (2004) Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 15: 411-419.
20. Wang ZB, Liu YQ, Cui YF, (2005) Pathways to caspase activation. Cell Biol Int 29: 489-496.
21. Afanasyeva EA, Komarova EY, Larsson LG, Bahram F, Margulis BA, et al. (2007) Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. Int J Cancer 121: 2615-2621.
22. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, et al. (2007) Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 6: 692-702.
23. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, et al. (2009) The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113: 4656-4666.
24. Song G, Chen GG, Hu T, Lai PB, (2010) Bid Stands at the Crossroad of Stress-response Pathways. Curr Cancer Drug Targets 10: 584-592.
25. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, et al. (2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928.
26. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, et al. (2004) Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18: 267-275.
27. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
28. Dai Y, Rahmani M, Pei XY, Dent P, Grant S, (2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and-independent mechanisms. Blood 104: 509-518.
29. Takada Y, Sethi G, Sung B, Aggarwal BB, (2008) Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Mol Pharmacol 73: 1549-1557.
30. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, et al. (2006) Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13: 748-758.
31. Mathieu J, Giraudier S, Lanotte M, Besancon F, (2005) Retinoid-induced activation of NF-kappaB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells. Oncogene 24: 7145-7155.
32. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, et al. (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem 274: 22532-22538.
33. Billen LP, Shamas-Din A, Andrews DW, (2008) Bid: a Bax-like BH3 protein. Oncogene 27 (Suppl 1): S93-104.
34. Decker RH, Wang S, Dai Y, Dent P, Grant S, (2002) Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther 1: 136-144.
35. Park C, Jin CY, Kim GY, Choi IW, Kwon TK, et al. (2008) Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol Appl Pharmacol 227: 219-228.
36. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W, (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12: 382-393.
37. Ploner C, Kofler R, Villunger A, (2009) Noxa: at the tip of the balance between life and death. Oncogene 27 (Suppl 1): S84-92.
38. Dalle S, Quoyer J, Varin E, Costes S, (2011) Roles and Regulation of the Transcription Factor CREB in Pancreatic b-Cells. Curr Mol Pharmacol.
39. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, et al. (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10: 13-29.
40. Liao Y, Hung MC, (2010) Physiological regulation of Akt activity and stability. Am J Transl Res 2: 19-42.
41. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, et al. (2004) p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 3: 895-902.
42. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, et al. (2004) Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 103: 291-300.
43. Martelli AM, Cocco L, Capitani S, Miscia S, Papa S, et al. (2007) Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis. Eur J Histochem 51 (Suppl 1): 125-131.
44. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512.
45. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, et al. (2010) Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24: 1686-1699.
46. Calleja V, Laguerre M, Parker PJ, Larijani B, (2009) Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 7: 189-200.
47. Hers I, Vincent EE, Tavare JM, (2011) Akt signalling in health and disease. Cell Signal, in press.
48. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408.
49. Sedlacek HH, (2001) Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38: 139-170.
50. Takada Y, Aggarwal BB, (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279: 4750-4759.
51. Giles FJ, Albitar M, (2005) Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5: 653-661.
52. Peng A, Maller JL, (2010) Serine/threonine phosphatases in the DNA damage response and cancer. Oncogene 29: 5977-5988.
53. Millward TA, Zolnierowicz S, Hemmings BA, (1999) Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191.
54. Yamamoto M, Suzuki Y, Kihira H, Miwa H, Kita K, et al. (1999) Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells. Leukemia 13: 595-600.
55. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, et al. (2011) PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25: 606-614.
56. Duncan JS, Turowec JP, Vilk G, Li SS, Gloor GB, et al. (2010) Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochim Biophys Acta 1804: 505-510.
57. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, et al. (2008) Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111: 3742-3750.
58. Guan L, Huang F, Li Z, Han B, Jiang Q, et al. (2008) P53 transcription-independent activity mediates selenite-induced acute promyelocytic leukemia NB4 cell apoptosis. BMB Rep 41: 745-750.
59. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, et al. (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79: 2378-2383.
60. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G, (2007) Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 92: 1224-1229.
61. Zanoli P, (2004) Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev 10: 203-218.
62. Schulz HU, Schurer M, Bassler D, Weiser D, (2005) Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 55: 15-22.
63. Wurglics M, Schubert-Zsilavecz M, (2006) Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45: 449-468.
64. Stock W, (2006) Controversies in treatment of AML: case-based discussion. Hematology Am Soc Hematol Educ Program pp. 185-191.
65. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
66. Sonneveld P, List AF, (2001) Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 14: 211-233.
67. Quiney C, Billard C, Faussat AM, Salanoubat C, Kolb JP, (2007) Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma 48: 1587-1599.
68. Komeno Y, Kitaura J, Kitamura T, (2009) Molecular bases of myelodysplastic syndromes: lessons from animal models. J Cell Physiol 219: 529-534.
69. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, et al. (2010) Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 115: 1406-1415.
70. Stoddart A, Tennant TR, Fernald AA, Anastasi J, Brodsky FM, et al. (2011) The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. Oncogene.
71. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, et al. (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18: 1333-1349.
72. Meuillet EJ, (2011) Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Curr Med Chem, in press.
73. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, et al. (2005) Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 19: 1760-1767.
74. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.
75. Fourneron JD, Naït-Si Y, (2006) Effect of eluent pH on HPLC/UV analysis of hyperforin. Phytochem Anal 17: 71-77.
76. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, et al. (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302.
77. Kim YR, Abraham NG, Lutton JD, (1991) Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)2 vitamin D3. Leuk Res 15: 409-418.
78. Trayner ID, Bustorff T, Etches AE, Mufti GJ, Foss Y, et al. (1998) Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res 22: 537-547.
79. Bauvois B, Van Weyenbergh J, Rouillard D, Wietzerbin J, (1996) TGF-beta 1-stimulated adhesion of human mononuclear phagocytes to fibronectin and laminin is abolished by IFN-gamma: dependence on alpha 5 beta 1 and beta 2 integrins. Exp Cell Res 222: 209-217.
80. Sanceau J, Boyd DD, Seiki M, Bauvois B, (2002) Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B. J Biol Chem 277: 35766-35775.